QTNT 13.15 Quotient Limited $QTNT Hit a 52 week high of 13.15 Closing the day 09:44 at 13.15 +0.28 +2.18% With a day low of 13.15 and a total volume of 1,600.
QTNT Recent Posts: http://investorshangout.com/Quotient-Limited-QTNT-90466/
QTNT Quotient Limited Recent Headline News
Quotient misses by $0.24, revenue in-line
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:51PM CST
QTNT: 13.15 (+0.28)
Quotient Limited Reports Second Quarter Fiscal 2015 Financial Results
GlobeNewswire - Mon Nov 03, 5:31PM CST
Quotient Limited ("Quotient"
(Nasdaq:QTNT), a commercial-stage diagnostics company, today reported financial results for its fiscal second quarter and six months ended September 30, 2014.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient reports November 3
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 7:35AM CDT
QTNT: 13.15 (+0.28)
Quotient Limited to Report Second Quarter Fiscal 2015 Financial Results and Host Conference Call
GlobeNewswire - Tue Oct 21, 7:01AM CDT
Quotient Limited ("Quotient" (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ending September 30, 2014 will be released after market close on Monday, November 3, 2014.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Launches Four New Reagent Red Cell Products
GlobeNewswire - Tue Oct 14, 7:08AM CDT
Quotient Limited ("Quotient" (Nasdaq:QTNT), an established, commercial-stage diagnostics company, today announced the approval and launch of four new products to expand its reagent red cell product offering.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Appoints Heino von Prondzynski to Board of Directors
GlobeNewswire - Tue Sep 09, 8:12AM CDT
Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Heino von Prondzynski to the Company's Board of Directors. Mr. von Prondzynski will also serve as the Company's Lead Independent Director. Mr. von Prondzynski brings strong executive management and diverse global experience from leadership positions held at several major multinational healthcare companies.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Limited to Present at the Baird 2014 Healthcare Conference
GlobeNewswire - Tue Sep 02, 1:27PM CDT
Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that Paul Cowan, Chairman and Chief Executive Officer, will present at the Baird 2014 Healthcare Conference in New York City at 2:20 p.m. Eastern Time on Wednesday, September 3.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
CORRECTION -- Quotient Reports First Quarter Fiscal 2015 Financial Results
GlobeNewswire - Mon Aug 04, 5:40PM CDT
In a press release issued earlier today by Quotient Limited ("Quotient" (Nasdaq:QTNT), please be advised that a reference to second quarter of fiscal 2014 was made in error, appearing in the fifth bullet under the section MosaiQ(TM) - Key Highlights. The corrected bullet follows.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Reports First Quarter Fiscal 2015 Financial Results
GlobeNewswire - Mon Aug 04, 3:15PM CDT
Quotient Limited ("Quotient" (Nasdaq:QTNT), a commercial-stage diagnostics company, today reported financial results for its fiscal first quarter ended June 30, 2014.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Appoints Sarah O'Connor to Board of Directors
GlobeNewswire - Mon Aug 04, 7:04AM CDT
Quotient Limited ("Quotient" (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Sarah O'Connor to the Company's Board of Directors. Ms. O'Connor will also serve on the Board's Nominating and Corporate Governance Committee. Most recently, Ms. O'Connor served as Senior Vice President, Strategic Development and Chief Legal Officer of Arch Chemicals, Inc., a publicly traded biocides company with sales of over $1.0 billion acquired by Lonza Group Ltd in October of 2011. "Sarah brings over twenty-five years experience as a senior executive within a number of major US corporations, where she held key positions spanning legal affairs and corporate governance, strategic planning and development and risk management," commented Paul Cowan, Quotient's Chairman and Chief Executive Officer. "We are delighted to have Sarah join our Board and we look forward to working with her as we transform the global transfusion diagnostic marketplace."
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Limited to Report First Quarter Fiscal 2015 Financial Results and Host Conference Call
GlobeNewswire - Tue Jul 22, 3:35PM CDT
Quotient Limited ("Quotient" (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ending June 30, 2014 will be released after market close on Monday, August 4, 2014.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Technical Feasibility Established for MosaiQ(TM) CMV and Syphilis Disease Screening Assays
GlobeNewswire - Mon Jun 23, 7:30AM CDT
Quotient Limited ("Quotient" (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that results generated using the MosaiQ(TM) methodology demonstrated a high degree of concordance to predicate technologies screening blood for Cytomegalovirus (CMV) and Syphilis. The feasibility study was conducted in collaboration with Future Diagnostics Solutions B.V. (Wijchen, The Netherlands) and examined a total of 274 positive and negative samples.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
QTNT Recent Posts: http://investorshangout.com/Quotient-Limited-QTNT-90466/
QTNT Quotient Limited Recent Headline News
Quotient misses by $0.24, revenue in-line
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:51PM CST
QTNT: 13.15 (+0.28)
Quotient Limited Reports Second Quarter Fiscal 2015 Financial Results
GlobeNewswire - Mon Nov 03, 5:31PM CST
Quotient Limited ("Quotient"
(Nasdaq:QTNT), a commercial-stage diagnostics company, today reported financial results for its fiscal second quarter and six months ended September 30, 2014. QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient reports November 3
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 7:35AM CDT
QTNT: 13.15 (+0.28)
Quotient Limited to Report Second Quarter Fiscal 2015 Financial Results and Host Conference Call
GlobeNewswire - Tue Oct 21, 7:01AM CDT
Quotient Limited ("Quotient"
(Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ending September 30, 2014 will be released after market close on Monday, November 3, 2014. QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Launches Four New Reagent Red Cell Products
GlobeNewswire - Tue Oct 14, 7:08AM CDT
Quotient Limited ("Quotient"
(Nasdaq:QTNT), an established, commercial-stage diagnostics company, today announced the approval and launch of four new products to expand its reagent red cell product offering. QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Appoints Heino von Prondzynski to Board of Directors
GlobeNewswire - Tue Sep 09, 8:12AM CDT
Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Heino von Prondzynski to the Company's Board of Directors. Mr. von Prondzynski will also serve as the Company's Lead Independent Director. Mr. von Prondzynski brings strong executive management and diverse global experience from leadership positions held at several major multinational healthcare companies.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Limited to Present at the Baird 2014 Healthcare Conference
GlobeNewswire - Tue Sep 02, 1:27PM CDT
Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that Paul Cowan, Chairman and Chief Executive Officer, will present at the Baird 2014 Healthcare Conference in New York City at 2:20 p.m. Eastern Time on Wednesday, September 3.
QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
CORRECTION -- Quotient Reports First Quarter Fiscal 2015 Financial Results
GlobeNewswire - Mon Aug 04, 5:40PM CDT
In a press release issued earlier today by Quotient Limited ("Quotient"
(Nasdaq:QTNT), please be advised that a reference to second quarter of fiscal 2014 was made in error, appearing in the fifth bullet under the section MosaiQ(TM) - Key Highlights. The corrected bullet follows. QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Reports First Quarter Fiscal 2015 Financial Results
GlobeNewswire - Mon Aug 04, 3:15PM CDT
Quotient Limited ("Quotient"
(Nasdaq:QTNT), a commercial-stage diagnostics company, today reported financial results for its fiscal first quarter ended June 30, 2014. QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Appoints Sarah O'Connor to Board of Directors
GlobeNewswire - Mon Aug 04, 7:04AM CDT
Quotient Limited ("Quotient"
(Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Sarah O'Connor to the Company's Board of Directors. Ms. O'Connor will also serve on the Board's Nominating and Corporate Governance Committee. Most recently, Ms. O'Connor served as Senior Vice President, Strategic Development and Chief Legal Officer of Arch Chemicals, Inc., a publicly traded biocides company with sales of over $1.0 billion acquired by Lonza Group Ltd in October of 2011. "Sarah brings over twenty-five years experience as a senior executive within a number of major US corporations, where she held key positions spanning legal affairs and corporate governance, strategic planning and development and risk management," commented Paul Cowan, Quotient's Chairman and Chief Executive Officer. "We are delighted to have Sarah join our Board and we look forward to working with her as we transform the global transfusion diagnostic marketplace." QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Quotient Limited to Report First Quarter Fiscal 2015 Financial Results and Host Conference Call
GlobeNewswire - Tue Jul 22, 3:35PM CDT
Quotient Limited ("Quotient"
(Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ending June 30, 2014 will be released after market close on Monday, August 4, 2014. QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
Technical Feasibility Established for MosaiQ(TM) CMV and Syphilis Disease Screening Assays
GlobeNewswire - Mon Jun 23, 7:30AM CDT
Quotient Limited ("Quotient"
(Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that results generated using the MosaiQ(TM) methodology demonstrated a high degree of concordance to predicate technologies screening blood for Cytomegalovirus (CMV) and Syphilis. The feasibility study was conducted in collaboration with Future Diagnostics Solutions B.V. (Wijchen, The Netherlands) and examined a total of 274 positive and negative samples. QTNT: 13.15 (+0.28), QTNTU: 6.61 (-0.24)
